Abstract
Wolfram syndrome 1 (WS1) is a rare autosomal recessive neurodegenerative disease characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and other abnormalities. WS1 usually results in death before the age of 50 years. The pathogenesis of WS1 is ascribed to mutations of human WFS1 gene on chromosome 4p encoding a transmembrane protein called wolframin, which has physiological functions in membrane trafficking, secretion, processing, and/or regulation of ER calcium homeostasis. Different types of WFS1 mutations have been identified, and some of these have been associated with a dominant, severe type of WS. Mutations of CISD2 gene cause autosomal recessive Wolfram syndrome 2 (WS2) characterized by the absence of diabetes insipidus and psychiatric disorders, and by bleeding upper intestinal ulcer and defective platelet aggregation. Other WFS1-related disorders such as DFNA6/14/38 nonsyndromic low-frequency sensorineural hearing loss and Wolfram syndrome-like disease with autosomal dominant transmission have been described. WS1 is a devastating disease for the patients and their families. Thus, early diagnosis is imperative to enable proper prognostication, prevent complications, and reduce the transmission to further progeny. Although there is currently no effective therapy, potential new drugs have been introduced, attempting to improve the progression of this fatal disease.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Change history
10 October 2018
The original version of this Article erroneously cropped part of the abstract. The abstract has now been corrected in the PDF and HTML versions of this Article.
References
Wolfram DJ, Wagener HP . Diabetes mellitus and simple optic atrophy among siblings: report of four cases. Mayo Clin Proc 1938;13:715–718.
Page MM, Asmal AC, Edwards CR . Recessive inheritance of diabetes: the syndrome of diabetes insipidus, diabetes mellitus, optic atrophy and deafness. Q J Med 1976;45:505–520.
Cremers CW, Wijdeveld PG, Pinckers AJ . Juvenile diabetes mellitus, optic atrophy, hearing loss, diabetes insipidus, atonia of the urinary tract and bladder, and other abnormalities (Wolfram syndrome). A review of 88 cases from the literature with personal observations on 3 new patients. Acta Paediatr Scand Suppl 1977;264:1–16.
Fraser FC, Gunn T . Diabetes mellitus, diabetes insipidus, and optic atrophy. An autosomal recessive syndrome? J Med Genet 1977;14:190–193.
Barrett TG, Bundey SE, Macleod AF . Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995;346:1458–1463.
Kumar S . Wolfram syndrome: important implications for pediatricians and pediatric endocrinologists. Pediatr Diabetes 2010;11:28–37.
Matsunaga K, Tanabe K, Inoue H et al. Wolfram syndrome in the Japanese population; molecular analysis of WFS1 gene and characterization of clinical features. PLoS ONE 2014;9:e106906.
Medlej R, Wasson J, Baz P et al. Diabetes mellitus and optic atrophy: a study of Wolfram syndrome in the Lebanese population. J Clin Endocrinol Metab 2004;89:1656–1661.
Lombardo F, Salzano G, Di Bella C et al. Phenotypical and genotypical expression of Wolfram syndrome in 12 patients from a Sicilian district where this syndrome might not be so infrequent as generally expected. J Endocrinol Invest 2014;37:195–202.
Zmyslowska A, Borowiec M, Fichna P et al. Delayed recognition of Wolfram syndrome frequently misdiagnosed as type 1diabetes with early chronic complications. Exp Clin Endocrinol Diabetes 2014;122:35–38.
Inoue H, Tanizawa Y, Wasson J et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998;20:143–148.
Strom TM, Hörtnagel K, Hofmann S et al. Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum Mol Genet 1998;7:2021–2028.
Hofmann S, Philbrook C, Gerbitz KD et al. Wolfram syndrome: structural and functional analyses of mutant and wild-type wolframin, the WFS1 gene product. Hum Mol Genet 2003;12:2003–2012.
Takeda K, Inoue H, Tanizawa Y et al. WFS1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum Mol Genet 2001;10:477–484.
Fonseca SG, Ishigaki S, Oslowski CM et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest 2010;120:744–755.
Amr S, Heisey C, Zhang M et al. A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. Am J Hum Genet 2007;81:673–683.
al-Sheyyab M, Jarrah N, Younis E et al. Bleeding tendency in Wolfram syndrome: a newly identified feature with phenotype genotype correlation. Eur J Pediatr 2001;160:243–246.
Solovyova N, Veselovsky N, Toescu EC et al. Ca(2+) dynamics in the lumen of the endoplasmic reticulum in sensory neurons: direct visualization of Ca(2+)-induced Ca(2+) release triggered by physiological Ca(2+) entry. EMBO J 2002;21:622–630.
Chen YF, Wu CY, Kirby R et al. A role for the CISD2 gene in lifespan control and human disease. Ann N Y Acad Sci 2010;1201:58–64.
Chen YF, Kao CH, Chen YT et al. Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice. Genes Dev 2009;15:1183–1194.
Wang CH, Tsai TF, Wei YH . Role of mitochondrial dysfunction and dysregulation of Ca(2+) homeostasis in insulin insensitivity of mammalian cells. Ann N Y Acad Sci 2015;1350:66–76.
Chang NC, Nguyen M, Germain M et al. Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1. EMBO J 2010;3:606–618.
Rouzier C, Moore D, Delorme C et al. A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions. Hum Mol Genet 2017;1:1599–1611.
Ishihara H, Takeda S, Tamura A et al. Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 2004;13:1159–1170.
Yamada T, Ishihara H, Tamura A et al. WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. Hum Mol Genet 2006;15:1600–1609.
Osman AA, Saito M, Makepeace C et al. Wolframin expression induces novel ion channel activity in endoplasmic reticulum membranes and increases intracellular calcium. J Biol Chem 2003;278:52755–52762.
Kim J, Xu W, Reed JC . Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008;7:1013–1030.
Sütt S, Altpere A, Reimets R et al. Wfs1-deficient animals have brain-region-specific changes of Na+, K+-ATPase activity and mRNA expression of α1 and β1 subunits. J Neurosci Res 2015;93:530–537.
Yurimoto S, Hatano N, Tsuchiya M et al. Identification and characterization of wolframin, the product of the wolfram syndrome gene (WFS1), as a novel calmodulin-binding protein. Biochemistry 2009;48:3946–3955.
Cagalinec M, Liiv M, Hodurova Z et al. Role of mitochondrial dynamics in neuronal development: mechanism for Wolfram syndrome. PLoS Biol 2016;19:e1002511.
Hilson JB, Merchant SN, Adams JC et al. Wolfram syndrome: a clinicopathologic correlation. Acta Neuropathol 2009;118:415–428.
Ito S, Sakakibara R, Hattori T . Wolfram syndrome presenting marked brain MR imaging abnormalities with few neurologic abnormalities. AJNR Am J Neuroradiol 2007;28:305–306.
Kawano J, Fujinaga R, Yamamoto-Hanada K et al. Wolfram syndrome 1 (Wfs1) mRNA expression in the normal mouse brain during postnatal development. Neurosci Res 2009;64:213–230.
Tekko T, Lilleväli K, Luuk H et al. Initiation and developmental dynamics of Wfs1 expression in the context of neural differentiation and ER stress in mouse forebrain. Int J Dev Neurosci 2014;35:80–88.
Kõks S, Overall RW, Ivask M et al. Silencing of the WFS1 gene in HEK cells induces pathways related to neurodegeneration and mitochondrial damage. Physiol Genomics 2013;45:182–190.
Westermark GT, Westermark P . Transthyretin and amyloid in the islets of Langerhans in type-2 diabetes. Exp Diabetes Res 2008;2008:429274 1-7.
Hershey T, Lugar HM, Shimony JS et al. Early brain vulnerability in Wolfram syndrome. PLoS ONE 2012;7:e40604.
Shang L, Hua H, Foo K et al. β-cell dysfunction due to increased ER stress in a stem cell model of Wolfram syndrome. Diabetes 2014;63:923–933.
Lemaire K, Schuit F . Integrating insulin secretion and ER stress in pancreatic β-cells. Nat Cell Biol 2012;14:979–981.
Fonseca SG, Fukuma M, Lipson KL et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. J Biol Chem 2005;280:39609–39615.
Akiyama M, Hatanaka M, Ohta Y et al. Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice. Diabetologia 2009;52:653–663.
Hatanaka M, Tanabe K, Yanai A et al. Wolfram syndrome 1 gene (WFS1) product localizes to secretory granules and determines granule acidification in pancreatic beta-cells. Hum Mol Genet 2011;20:1274–1284.
Tein K, Kasvandik S, Kõks S et al. Prohormone convertase 2 activity is increased in the hippocampus of Wfs1 knockout mice. Front Mol Neurosci 2015;8:45–50.
Xu R, Xia B, Geng J et al. Expression and localization of Wolfram syndrome 1 gene in the developing rat pancreas. World J Gastroenterol 2009;15:5425–5431.
Ivask M, Hugill A, Kõks S . RNA-sequencing of WFS1-deficient pancreatic islets. Physiol Rep 2016;4:e12750.
Sethupathy P, Collins FS . MicroRNA target site polymorphisms and human disease. Trends Genet 2008;24:489–497.
Kovacs-Nagy R, Elek Z, Szekely A et al. Association of aggression with a novel microRNA binding site polymorphism in the wolframin gene. Am J Med Genet B Neuropsychiatr Genet 2013;162B:404–412.
Chaussenot A, Rouzier C, Quere M et al. Mutation update and uncommon phenotypes in a French cohort of 96 patients with WFS1-related disorders. Clin Genet 2015;87:430–439.
d'Annunzio G, Minuto N, D'Amato E et al. Wolfram syndrome (diabetes insipidus, diabetes, optic atrophy, and deafness): clinical and genetic study. Diabetes Care 2008;31:1743–1745.
Cano A, Rouzier C, Monnot S et al. Identification of novel mutations in WFS1 and genotype-phenotype correlation in Wolfram syndrome. Am J Med Genet A 2007;143A:1605–1612.
Rohayem J, Ehlers C, Wiedemann B et al. Diabetes and neurodegeneration in Wolfram syndrome: a multicenter study of phenotype and genotype. Diabetes Care 2011;34:1503–1510.
Chaussenot A, Bannwarth S, Rouzier C et al. Neurologic features and genotype-phenotype correlation in Wolfram syndrome. Ann Neurol 2011;69:501–508.
deHeredia ML, Clèries R, Nunes V . Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype. Genet Med 2013;15:497–506.
Bonnycastle LL, Chines PS, Hara T et al. Autosomal dominant diabetes arising from a Wolfram syndrome 1 mutation. Diabetes 2013;62:3943–3950.
Morikawa S, Tajima T, Nakamura A et al. A novel heterozygous mutation of the WFS1 gene leading to constitutive endoplasmic reticulum stress is the cause of Wolfram syndrome. Pediatr Diabetes 2017;8:1–8.
De Franco E, Flanagan SE, Yagi T et al. Dominant ER stress-inducing wfs1 mutations underlie a genetic syndrome of neonatal/infancy-onset diabetes, congenital sensorineural deafness, and congenital cataracts. Diabetes 2017;66:2044–2053.
Rigoli L, Lombardo F, Di Bella C . Wolfram syndrome and WFS1 gene. Clin Genet 2011;79:103–117.
Rigoli L, Lombardo F, Salzano G et al. Identification of one novel causative mutation in exon 4 of WFS1 gene in two Italian siblings with classical DIDMOAD syndrome phenotype. Gene 2013;526:487–489.
Ganie MA, Bhat D . Current developments in Wolfram syndrome. J Pediatr Endocrinol Metab 2009;22:3–10.
Cano A, Molines L, Valéro R et al. Microvascular diabetes complications in Wolfram syndrome (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness [DIDMOAD]): an age- and duration-matched comparison with common type 1 diabetes. Diabetes Care 2007;30:2327–2330.
Zmyslowska A, Fendler W, Niwald A et al. Retinal thinning as a marker of disease progression in patients with Wolfram syndrome. Diabetes Care 2015;38:e36–e37.
Hoekel J, Chisholm SA, Al-Lozi A et al. Ophthalmologic correlates of disease severity in children and adolescents with Wolfram syndrome. J AAPOS 2014;18:461–465.
Cremers CW, Wijdeveld PG, Pinckers AJ . Juvenile diabetes mellitus, optic atrophy, hearing loss, diabetes insipidus, atonia of the urinary tract and bladder, and other abnormalities (Wolfram syndrome). A review of 88 cases from the literature with personal observations on 3 new patients. Acta Paediatr Scand Suppl. 1977;264:1–16.
Gunn T, Bortolussi R, Little JM et al. Juvenile diabetes mellitus, optic atrophy, sensory nerve deafness, and diabetes insipidus—a syndrome. J Pediatr 1976;89:565–570.
Barrett TG, Bundey SE . Wolfram (DIDMOAD) syndrome. J Med Genet 1997;34:838–841.
Al-Till M, Jarrah NS, Ajlouni KM . Ophthalmologic findings in fifteen patients with Wolfram syndrome. Eur J Ophthalmol 2002;12:84–88.
Dhalla MS, Desai UR, Zuckerbrod DS . Pigmentary maculopathy in a patient with Wolfram syndrome. Can J Ophthalmol 2006;41:38–40.
Chacón-Camacho O, Arce-Gonzalez R, Granillo-Alvarez M et al. Expansion of the clinical ocular spectrum of Wolfram Syndrome in a family carrying a novel WFS1 gene deletion. Ophthalmic Genet 2013;34:243–248.
Zmyslowska A, Fendler W, Szadkowska A et al. Glycemic variability in patients with Wolfram syndrome is lower than in insulin-dependent diabetes mellitus. Acta Diabetol 2015: 29–32.
Bababeygy SR, Wang MY, Khaderi KR et al. Visual improvement with the use of idebenone in the treatment of Wolfram syndrome. J Neuroophthalmol 2012;32:386–389.
Lu S, Kanekura K, Hara T et al. A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. Proc Natl Acad Sci USA 2014;9:E5292–E5301.
Pennings RJ, Huygen PL, van den Ouweland JM et al. Sex-related hearing impairment in Wolfram syndrome patients identified by inactivating WFS1 mutations. Audiol Neurootol 2004;9:51–62.
Bischoff AN, Reiersen AM, Buttlaire A et al. Selective cognitive and psychiatric manifestations in Wolfram Syndrome. Orphanet J Rare Dis 2015;10:66–69.
Fukuma M, Ariyasu D, Hatano M et al. Early-onset urological disorders due to Wolfram syndrome: A case of neonatal onset. Clin Pediatr Endocrinol 2016;25:67–69.
Tranebjaerg L . WFS1-Related Disorders. GeneReviews 2014. http://www.gentests.org.
Kinsley BT, Swift M, Dumont RH et al. Morbidity and mortality in the Wolfram syndrome. Diabetes Care 1995;18:1566–1570.
Aloi C, Salina A, Pasquali L et al. Wolfram syndrome: new mutations, different phenotype. PLoS ONE 2012;7:e29150.
Cryns K, Sivakumaran TA, Van den Ouweland JM et al. Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Mutat 2003;22:275–287.
Lesperance MM, Hall JW 3rd, San Agustin TB et al. Mutations in the Wolfram syndrome type 1 gene (WFS1) define a clinical entity of dominant low-frequency sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 2003;129:411–420.
Sun Y, Cheng J, Lu Y et al. Identification of two novel missense WFS1 mutations, H696Y and R703H, in patients with non-syndromic low-frequency sensorineural hearing loss. J Genet Genomics 2011;38:71–76.
Rigoli L, Di Bella C . Wolfram syndrome 1 and Wolfram syndrome 2. Curr Opin Pediatr 2012;24:512–517.
Valéro R, Bannwarth S, Roman S et al. Autosomal dominant transmission of diabetes and congenital hearing impairment secondary to a missense mutation in the WFS1 gene. Diabet Med 2008;25:657–661.
Eiberg H, Hansen L, Kjer B et al. Autosomal dominant optic atrophy associated with hearing impairment and impaired glucose regulation caused by a missense mutation in the WFS1 gene. J Med Genet 2006;43:435–440.
Calamini B, Morimoto RI . Protein homeostasis as a therapeutic target for diseases of protein conformation. Curr Top Med Chem 2012;12:2623–2640.
Zatyka M, Da Silva Xavier G, Bellomo EA et al. Sarco(endo)plasmic reticulum ATPase is a molecular partner of Wolfram syndrome 1 protein, which negatively regulates its expression. Hum Mol Genet. 2015;24:814–827.
Urano F . Wolfram syndrome iPS cells: the first human cell model of endoplasmic reticulum disease. Diabetes 2014;63:844–846.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
Publisher’s note:
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rigoli, L., Bramanti, P., Di Bella, C. et al. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res 83, 921–929 (2018). https://doi.org/10.1038/pr.2018.17
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/pr.2018.17
This article is cited by
-
Evaluation of pathogenic variant in WFS1 in a patient with Wolfram syndrome
Egyptian Journal of Medical Human Genetics (2025)
-
A WFS1 variant disrupting acceptor splice site uncovers the impact of alternative splicing on beta cell apoptosis in a patient with Wolfram syndrome
Diabetologia (2025)
-
ISR inhibition reverses pancreatic β-cell failure in Wolfram syndrome models
Cell Death & Differentiation (2024)
-
A deep phenotyping study in mouse and iPSC models to understand the role of oligodendroglia in optic neuropathy in Wolfram syndrome
Acta Neuropathologica Communications (2024)
-
A p.Val412Serfs pathogenic variant associated with Wolfram-like syndrome and leukodystrophy
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (2023)
